7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective proof-of-concept interventional study will enroll about 30 adults with CT evidence of a lung nodule suspicious for lepidic-predominant adenocarcinoma or histologically confirmed disease. Participants receive an individualized ketogenic diet for seven days prior to FDG PET/CT, with dietary assessments and basic labs performed on the day of imaging. PET/CT images will be independently read by two board-certified nuclear medicine physicians and compared against histopathology as the reference standard. Study-level results will also be compared with literature-reported diagnostic performance and a matched retrospective institutional cohort.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent.
* Age 18 years or older.
* CT evidence of a lung nodule suspicious for LPA or lung biopsy positive for LPA.
* Target nodule diameter at least 10 mm.
* ECOG performance status 0 to 2.
* Willingness and ability to adhere to a controlled ketogenic diet for 7 days.
* Ability to comply with study procedures and visit schedule.

Exclusion Criteria:

* Not suitable for prolonged imaging procedures.
* Renal failure.
* Type 1 diabetes mellitus.
* Pancreatitis.
* Severe dyslipidemia.
* Other malignancies that are progressing or required active treatment within the previous 3 years.
* Serious or unstable medical, psychiatric, or substance use disorders that could interfere with study participation.
* Pregnancy or breastfeeding.
* Refusal to participate

Where it's running

• Fondazione del Piemonte per l'Oncologia- IRCCS Istituto di Candiolo, Candiolo, Turin 10060
  Candiolo, Torino (TO), Italy Recruiting

Study contacts

• Study coordinator: Alessio Rizzo, MD
• Email: alessio.rizzo@ircc.it
• Phone: 0119933794

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions

  This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.

  Recruiting Sheba Medical Center · Ramat Gan, Israel · NCT07636252

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• Partial high-dose tumor irradiation combined with immunotherapy for unresectable lung adenocarcinoma

  This trial will try giving very high-dose radiation to the central part of large, unresectable lung adenocarcinomas while preserving the surrounding immune tissue and pairing that with an immune checkpoint drug for patients who have no remaining standard treatment options.

  Recruiting Karl Landsteiner University of Health Sciences · Krems, Austria · NCT07423169

• PHOENIX: QL1706 plus chemo and bevacizumab in high PD-L1, driver-mutant non-squamous NSCLC

  This trial tests if adding QL1706 to chemotherapy and bevacizumab can help patients with PD-L1 high, driver-mutant non-squamous NSCLC after TKIs.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong,China and 1 other locations · NCT07416058

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.